Inclusion Criteria:

   - Weigh between 35-135 kilograms

   - Low or int-1 risk MDS

   - Ferritin >1000 micrograms/liter at screening

   - History of transfusion of 15 to 75 Packed Red Blood Cells (PRBC) units

   - Anticipated to be transfused with at least 8 units of PRBCs annually during the study

   - Women of child-bearing potential using effective methods of contraception during
   dosing of study treatment

Exclusion Criteria:

   - More than 6 months of cumulative ICT (such as daily deferasirox (Exjade®) or
   deferiprone or 5×/week deferoxamine)

   - More than 3 years since patient began receiving regular transfusions (2 units per 8
   weeks or 4 units received in a 3 month period)

   - Significant proteinuria

   - History of hospitalization for congestive heart failure; other heart conditions as
   specified in the protocol

   - Systemic diseases which would prevent study treatment

   - Hepatitis B; Hepatitis C; HIV

   - Liver cirrhosis

   - Pregnant, or breast-feeding patients, or patients of child-bearing potential not
   employing an effective method of birth control

   - History of drug or alcohol abuse within the 12 months prior to enrollment